Rhythm Pharmaceuticals, Inc.
A biopharmaceutical company that makes medicines for rare genetic diseases of severe obesity, marked by insatiable hunger and excess weight gain. Its marketed drug, IMCIVREE (setmelanotide), is a precision medicine that restores a signaling pathway in the brain controlling hunger and fullness for patients with conditions such as Bardet-Biedl syndrome and POMC deficiency. Founded in 2008 in Boston, the company's name echoes the body's internal rhythm of hunger and metabolism its medicines aim to reset.
Granted 260.8K · Sold 107.6K
Granted 290.9K · Sold 200.7K
Granted 184.3K · Sold 121.7K
Granted 213.7K · Sold 184.5K
Granted 183.1K · Sold 160.5K
Granted 269.3K · Sold 177.6K
Granted 7.0K
Granted 95.2K · Sold 83.5K
Granted 83.7K · Sold 72.0K
Granted 77.1K · Sold 65.4K
Granted 11.7K
Granted 11.7K
Granted 5.0K · Sold 2.9K
Granted 11.1K · Sold 1.3K
Granted 7.0K
Granted 4.1K · Sold 2.6K
Granted 20.3K · Sold 19.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Meeker David PPresident and CEO, Director · 13 transactions | +143% | 270.5K | 260.8K | — | 107.6K |
| Smith Hunter CChief Financial Officer · 75 transactions | +209.5% | 119.6K | 290.9K | — | 200.7K |
| Mazabraud YannEVP, Head of International · 24 transactions | — | 66.0K | 184.3K | — | 121.7K |
| Cramer Pamela J.Chief Human Resources Officer · 61 transactions | — | 29.4K | 213.7K | — | 184.5K |
| Lee Jennifer KaydenEVP, Head of North America · 53 transactions | — | 28.5K | 183.1K | — | 160.5K |
| Shulman JosephChief Technical Officer · 64 transactions | — | 25.5K | 269.3K | — | 177.6K |
| Mathers Edward TDirector · 5 transactions | — | 21.2K | 7.0K | — | — |
| Good Jennifer LDirector · 17 transactions | — | 11.7K | 95.2K | — | 83.5K |
| Tetrault LYNN A.Director · 17 transactions | — | 11.7K | 83.7K | — | 72.0K |
| McGirr David W JDirector · 6 transactions | — | 11.7K | 77.1K | — | 65.4K |
| Arbuckle Stuart ADirector · 3 transactions | — | 11.7K | 11.7K | — | — |
| Jean ChristopheDirector · 3 transactions | — | 11.7K | 11.7K | — | — |
| Roberts William T.Chief Accounting Officer · 5 transactions | — | 7.9Kas of Mar 2023 | 5.0K | — | 2.9K |
| Garfield AlastairChief Scientific Officer · 5 transactions | — | 7.8K | 11.1K | — | 1.3K |
| Bedrosian Camille LDirector · 2 transactions | — | 7.0Kas of Jun 2025 | 7.0K | — | — |
| Chien JenniferEVP, Head of North America · 5 transactions | — | 4.9Kas of Feb 2023 | 4.1K | — | 2.6K |
| German Christopher PaulCorporate Controller & CAO · 25 transactions | — | 1.9K | 20.3K | — | 19.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.20M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.